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To test the ability of high-throughput DNA sequencing 
to detect bacterial pathogens, we used it on DNA from a 
patient’s feces during and after diarrheal illness. Sequenc-
es showing best matches for Campylobacter jejuni were 
detected only in the illness sample. Various bacteria may be 
detectable with this metagenomic approach.
I
nfectious diseases are caused by various pathogens, in-
cluding as-yet unidentiﬁ   ed microorganisms. Because 
procedures for detecting and identifying pathogens vary ac-
cording to the target microorganism, clinical examinations 
require a variety of media, reagents, and culture methods. 
In addition, conventional examination protocols usually re-
quire much labor, time, and skill, thus forming an obstacle 
to a prompt diagnosis.
Newly developed, “next-generation” DNA sequencers 
can determine >100 megabases of DNA sequences per run 
(1). These new technologies eliminate the bacterial clon-
ing step used in traditional Sanger sequencing; instead, 
they amplify single isolated DNA molecules and analyze 
them with massively parallel processing. To develop a new 
system to promptly detect and identify various infectious 
pathogens, we tapped into the potential of these novel se-
quencers. We directly detected the causative pathogenic 
microbe in a clinical human sample (diarrheic feces) by 
means of unbiased high-throughput DNA sequencing.
The Study
A 34-year-old man had become ill after eating dinner 
out with his family. After 3 days, severe diarrhea, stomach 
ache, and shivering developed in the only 3 persons (the 
patient plus 2 family members) who had eaten undercooked 
chicken that night. Four days after onset of clinical signs, 
feces were collected from the patient and stored in a freezer 
at –80°C. At a clinical laboratory in Osaka, Japan, conven-
tional culture methods were used to examine the sample for 
possible bacterial enteropathogens (2), and speciﬁ  c reverse 
transcriptase–PCR was used to test for norovirus (3); how-
ever, no candidate pathogens were detected.
We therefore analyzed this fecal sample for possible 
pathogens by means of high-throughput DNA sequencing. 
DNA was extracted from the diarrhea sample (hereafter re-
ferred to as the illness DNA sample) with a QIAamp DNA 
Stool Mini Kit (QIAGEN, Valencia, CA, USA). After the 
man had completely recovered 3 months later, another fe-
cal sample was collected (hereafter referred to as the re-
covery DNA sample) and maintained at –80°C until DNA 
extraction. Both DNA samples were subjected to unbiased 
high-throughput DNA sequencing with a GS20 sequencer 
(454 Life Sciences, Branford, CT, USA) (4).
Sequencing produced 96,941 effective sequences 
for the illness DNA sample and 106,327 for the recovery 
sample. The average length of the sequences was 102.1 
bp. The DNA sequences obtained were searched with the 
BLASTN program for the National Center for Biotechnol-
ogy Information nucleotide sequence database (http://blast.
ncbi.nlm.nih.gov). The BLASTN output was then analyzed 
by using a classiﬁ  cation system consisting of the Center’s 
taxonomy database and its searching system. This system, 
devised with the aid of Perl language (www.perl.com) and 
the MySQL database (www.mysql.com), facilitates the 
identiﬁ  cation of scientiﬁ  c names and statistical analysis. 
The Figure shows the organisms from which the sequences 
in the database were derived that showed the best matches 
for the sequences queried (expect [E]-value <10–5). For 
both DNA samples, ≈20% of the total sequences showed 
the best matches for the currently reported bacterial DNA 
sequences. The Table shows the frequency distributions of 
species from which close matches for the sequences were 
derived (E-value <10–40). The most frequently detected 
bacterial species in both samples belonged to the phylum 
Bacteroidetes, the normal ﬂ  ora of the human intestine. No 
major differences were found in the frequency of the spe-
cies between the illness and recovery DNA samples.
A striking difference between the 2 samples, however, 
was that 156 sequences of the illness DNA sample showed 
best matches for the sequences derived from Campy-
lobacter jejuni, but no sequences of the recovery DNA 
sample showed any such signiﬁ  cant matches. The C. jejuni 
sequences from the illness DNA sample included many 
housekeeping genes, such as the genes for the ribosomal 
RNAs and DNA polymerases (online Appendix Table, 
available from www.cdc.gov/EID/content/14/11/1784-
appT.htm); thus, they strongly suggested the presence of C. 
jejuni in the illness fecal sample.
Because C. jejuni is a bacterium that causes acute gas-
troenteritis and is normally not present in the intestines of 
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healthy persons (5,6), these results prompted us to reex-
amine the illness fecal sample for C. jejuni. For the illness 
sample but not the recovery DNA sample, Campylobacter-
speciﬁ  c PCR (7) produced a typical banding pattern that is 
unique to C. jejuni (data not shown). The recovery rate of 
Campylobacter spp. from patient specimens substantially 
decreases when the specimens are frozen before isolation 
(8). To obtain higher recovery of Campylobacter spp. and 
thus validate the presence of C. jejuni in the illness sample, 
we performed cultures with enrichment and selective media 
again on the frozen illness fecal sample (5). C. jejuni–like 
bacteria with corkscrew motility grew on selective agar 
plates. Biochemical identiﬁ  cation using the API Campy kit 
(API-bioMérieux, Marcy L’Etoile, France) demonstrated 
that the organism was C. jejuni, thus proving its presence 
in the illness fecal sample.
Conclusions
We directly detected a bacterial pathogen in a patient 
sample by using high-throughput DNA sequencing. This 
ﬁ  nding implies that basically any kind of bacterial pathogen 
may be detectable with a common procedure. The method 
is directly applicable not only to fecal samples but also to 
other types of clinical samples; it could detect and identify 
bacterial pathogens that are usually difﬁ  cult to ascertain 
with conventional examination procedures. Because this 
novel approach can be expected to have major potential 
for detection of pathogens in various infectious diseases, it 
warrants further investigation.
The approach reported here also enabled us to directly 
analyze the ratio of pathogenic to commensal bacteria in 
the human intestine. Assessment of the relative popula-
tion of intestinal bacteria would enable us to investigate 
the dynamics of bacterial pathogens in human intestines, 
in relation to associated intestinal microbial ﬂ  ora, during 
infectious disease processes.
Many causative agents of emerging infectious diseases 
are of animal origin, and many are previously identiﬁ  ed 
microbes (9,10). Because a vast amount of genome infor-
mation about various microorganisms is continually be-
ing accumulated in databases, the approach we used will 
become increasingly useful. Recent metagenomic studies 
have identiﬁ  ed unknown virus pathogens (11–13). Using 
the present approach to analyze various clinical cases, es-
pecially of outbreaks of infectious diseases with as-yet un-
identiﬁ  ed causative agents, may lead to the discovery of 
novel bacteria that are currently not known to be patho-
genic to humans.
The current cost for high-throughput sequencing may 
limit the use of this method to specialized purposes, such 
as the hunt for novel pathogens for research or detection of 
bioterrorism (14). However, because the progress of DNA 
sequencing technology has been rapid (1), the cost, time, 
and labor for sequencing have been greatly reduced, and 
this trend will likely continue for the foreseeable future 
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Figure. Comparison of the organisms from which the best matches 
for the sequences were derived from a BLASTN (http://blast.ncbi.
nlm.nih.gov) search with an expect-value cutoff of 10–5. A) DNA 
from nondiarrheic fecal sample collected 3 months after patient 
had recovered. B) DNA from diarrheic fecal sample collected while 
patient was ill.
Eukaryotes
Bacteria
No hits
Proteobacteria
Bacteroidetes/
Chlorobi group
Firmicutes
Environmental 
samples
Others
A
B
Table. Frequency distributions of species in fecal samples taken 
from patient during illness and after recovery, as determined by 
BLASTN*
No. (%) 
Organism  Illness† Recovery‡ 
Bacteroides vulgatus 5,944 (50.5)  4,743 (56.5) 
Homo sapiens 2,955 (25.1)  84 (1.0) 
Parabacteroides distasonis 818 (6.9)  1,283 (15.3) 
B. thetaiotaomicron 767 (6.5)  1,046 (12.5) 
B. fragilis 759 (6.4)  842 (10.0) 
Uncultured bacterium  195 (1.7)  227 (2.7) 
Campylobacter jejuni 156 (1.3)  0
B. ovatus 48 (0.4)  63 (0.8) 
Uncultured Bacteroides spp. 20 (0.2)  19 (0.2) 
B. uniformis 14 (0.1)  8 (0.1) 
*BLASTN available from http://blast.ncbi.nlm.nih.gov. Expect-value cutoff 
10
–40.
†Diarrheic fecal sample collected while patient was ill. Total sequences 
96,941; total (100%) BLAST matches 11,777. 
‡Nondiarrheic fecal sample collected 3 mo after patient had recovered. 
Total sequences 106,327; total (100%) BLAST matches 8,397.  (15). Therefore, high-throughput DNA sequencing may 
soon be adopted as the main method for examining mi-
croorganisms in major clinical laboratories. The data pre-
sented here represent an example of this major innovation 
in the ﬁ  eld of clinical examination for causative agents of 
infectious diseases.
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